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Teaser Advances in molecular imaging have led to extraordinary progress, with several
strategies being deployed to understand the fate of stem cells in vivo. This review provides a
comprehensive and timely overview of recent advances, challenges and future perspectives of
different imaging modalities used in stem cell tracking and functional assessment.
Accomplishments and challenges in
stem cell imaging in vivo
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Medical Center, Dallas, TX 75390-8514, USA
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Stem cell therapies have demonstrated promising preclinical results, but
very few applications have reached the clinic owing to safety and efficacy
concerns. Translation would benefit greatly if stem cell survival,
distribution and function could be assessed in vivo post-transplantation,
particularly in patients. Advances in molecular imaging have led to
extraordinary progress, with several strategies being deployed to
understand the fate of stem cells in vivo using magnetic resonance,
scintigraphy, PET, ultrasound and optical imaging. Here, we review the
recent advances, challenges and future perspectives and opportunities in
stem cell tracking and functional assessment, as well as the advantages and
challenges of each imaging approach.
Introduction
The landscape of stem cell (SC) therapy has changed dramatically in recent years [1]. SCs of
embryonic (ESCs) [2], mesenchymal (MSCs) [3] and neuroprogenitor (NSCs) origin [4], as well as
induced pluripotent stem cells (iPSCs) [2,5,6], have garnered increased attention owing to their
therapeutic and regenerative potential. SCs have been used to treat diverse diseases such as
Parkinson’s disease [7] and liver disease [8], as well as to repair ischemic and infarcted tissues [9],
including acute myocardial infarction [10]. Efficacy of SC therapy has generally relied upon ex vivo
genetic manipulation or modifications using cytokines or small molecules [11], which alter SC
function and behavior profile; however, these changes can also induce unwanted side effects [12].
Therapeutic efficacy depends on several factors such as SC origin and source, route of adminis-
tration, biodistribution, cell survival after transplantation, as well as the disease itself [12,13]. The
ability to confirm SC accumulation in their intended target tissue, define acute and long-term
viability and desired function, determine their accumulation in non-desired locations and assess
their interaction with the host in a noninvasive manner would greatly enhance their safety and
efficacy [14,15]. Labeling SCs with reporters or reporter genes to enable their detection and assess
their function in vivo has been achieved using all current imaging modalities with promising
preclinical results, and with some success in clinical trials [16]. However, at present, there is no
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This review presents the approaches and achievements made with
each imaging modality, as well as advantages, limitations and
challenges for translation. We will highlight future advances in
SC imaging and present potential opportunities for image-guided
therapeutic intervention.
SC labeling techniques
Advances in SC labeling, imaging and tracking have enabled
longitudinal monitoring in vivo, as well as assessment of viability
and function [12], mostly in preclinical studies [17]. Direct or
indirect labeling of SCs with molecular probes has been achieved
with advantages and disadvantages to each approach [14,17].
Direct labeling involves the loading of SCs before engrafting with
a sufficient amount of reporters to enable their detection with the
imaging modality of choice. Although sufficient reporter concen-
tration enables SC imaging at the desired spatial and temporal
resolution, it suffers from several challenges, the most important
of which are reporter dilution as cells divide and migrate, reporter
rather than SC tracking and difficulty in assessing SC viability and
function. Indirect labeling involves the incorporation of a report-
er gene within SCs that require transfection with either viral or
nonviral carriers as well as sufficient transfection efficiency toLabeling stem cells
In vitro culture
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19FNPs
FIGURE 1
Cartoon summarizing various direct and indirect labeling strategies and the use o
cartoon were in part adopted from Servier Medical Art by Servier (https://smart
Attribution 3.0 Unported License.detect the expressed reporters when engrafted. Because the in-
troduced gene can only be expressed by live cells its detection
infers cell viability. Many reporter genes have been proposed,
where the expressed protein can be imaged directly, such as
florescent proteins [18], can trap iron to become detectable
[19], can be used as a receptor to target reporters [20] or can
be an enzyme that induces reporter trapping [21], or converts an
invisible to a visible reporter [22]. Although reporter genes over-
come some of the challenges of direct labeling, they have chal-
lenges of their own. Unless the gene is incorporated within the
genome, it has limited survival time, and also suffers from dilu-
tion effects with cell division and migration, albeit less than
direct reporter labeling. Further, the transfection strategy, partic-
ularly if viral vectors are used, and if the expressed protein reaches
the extracellular space, raises concern of mutagenesis, toxicity
and immune and allergic responses (Fig. 1)
Overview of SC imaging technologies
All imaging modalities have been attempted with a degree of
success for each approach dependent on the reporter used, labeling
strategy, cell concentration required for detection, spatial resolu-
tion, imaging time and the application itself. Advantages and
limitations of each approach are summarized in Table 1. At anyRegenerative
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TABLE 1
Summary of characteristics, reporters used and advances and limitations of each proposed stem cell in vivo imaging technique
Imaging
methods
Contrast agents Acquisition time Spatial resolution Minimum cells
#/voxel detected
in vivo
Method
suitability
Advantages Limitations
PET  F-18 (FDG, FHBG, FDOPA)
 64Cu-PTSM
 Sodium iodide symporter (NIS)
 HSV1-tk + F-18
acycloguanosine or pyrimidine
analog
Seconds to
minutes
>1–2 mm 10 000 cells Preclinical and
clinical
 3D imaging
 High sensitivity
 High labeling efficiency
 Able to image deep tissues
 Used clinically
 Expensive
 Low spatial resolution
 Anatomic reference required
 Concern for radiation dose
SPECT  99mTc-HMPAO
 In-111
 Sodium iodide symporter (NIS)
 Dopamine receptor
 HSV1-tk
Minutes >1–2 mm 100 000 cells Preclinical and
clinical
 3D imaging
 Can use multiple reporters
 Preferable method for large animal
studies
 Used clinically
 Limited spatial resolution
 Quantification is challenging
 Concern for radiation dose
MRI  Iron oxide nano- micro-
particles
 Gd chelates, Gd oxide NPs
 F-19 – perfluorocarbons
 Si-Gold NPs
 Metalloproteins
 Metal ion transporters
 Water channel aquaporin
 Lysine-rich protein
Minutes to hours Resolution scales with RF coil,
imaging time and reporter
concentration (from 50 mm to
5 mm)
10 000 cells Preclinical and
clinical
 Excellent tissue contrast
 Nonionizing
 Quantitative
 Long-term imaging ability (<1 month)
 Expensive
 Complex procedure
 Not all patients can be imaged
US  Gas filled MBs
 Detects endothelial cell gene
expression with targeted MBs
 Microcapsules
 Liposomes
Real-time Resolution scales with
frequency (50 mm at <1 cm, to
1–2 mm at 15–20 cm)
1–10 cells Preclinical and
clinical
 Extremely high sensitivity
 Real-time imaging to 20 cm depth of field
 Inexpensive, nonionizing, and portable
 Most common imaging tool worldwide
 Used for image-guided stem cell grafting
 limited 3D capabilities
 Limited quantification
 Not suitable for lung imaging
 Limited intracranial imaging
CT  Microcapsules
 Barium
 Gold nanoparticles
Seconds to
minutes
High resolution 20 mm in mice,
<1 mm in human
Unknown Preclinical and
clinical
 3D imaging
 Relatively inexpensive
 High resolution
 Very poor sensitivity
 Uses ionizing radiation
BLI  Chemiluminescent luciferase
reactions
<1 minute 1–20 mm depending on depth
of signal
1000 cells Preclinical  Less expensive
 High-throughput method
 More suitable for long-term imaging in
small animal studies
 Poor tissue penetration
 Low in vivo resolution
 Requires transfection of cells
 Not suitable clinically
FLI  Fluorescent dyes
 Fluorescent polymeric NPs
 Quantum dots (QDs)
 Fluorescent proteins (GFP,RFP,
. . . )
Real-time to
seconds to
minutes
1–10 mm depending on depth
of field and signal
1 000 000 cells Preclinical and
clinical
 Less expensive
 Ideal for ultra-high resolution microscopy
 Real-time
 Low resolution in vivo
 Poor tissue penetration
 Photobleaching
 Tissue autofluorescence
PAI  Optical absorbers Real-time <1 mm3 depending on field of
view
200–1000 cells Preclinical and
clinical
 Less expensive
 Real-time
 Higher resolution than US, FLI and BLI
 Limited penetration
 Not suitable for brain or lung
 Limited quantification
MPI  Iron oxide nano- micro-
particles
Seconds to
minutes
1 mm3 10 000 Preclinical  High contrast:noise ratio
 Hotspot imaging
 Not yet available for large
animal or human imaging
 Same limitations as MRI
 Requires multimodal imaging
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smallest detectable unit volume)], large voxels improve sensitivity
(increase voxel signal), decrease noise [higher signal:noise ratio
(SNR)] but also decrease spatial resolution. The higher the imaging
sensitivity the fewer reporters per voxel are needed for detection
and therefore the fewer SC per voxel that could be detected.
Therefore, each imaging approach aims to detect the minimum
number of SCs per voxel at the highest spatial resolution and
shortest imaging time, which is challenged in vivo by the addition
of motion that blurs images and decreases contrast:noise ratio
(CNR).
Detection sensitivity in vivo is highest for optical fluorescence
imaging (FLI) which can detect nanomolar concentrations with
greater concentrations needed for bioluminescence imaging (BLI).
This sensitivity is achieved at the expense of spatial resolution for
in vivo imaging that is 1 cm3, and has extremely limited depth of
penetration (<1 cm), because photons are highly scattered and
attenuated in tissues. Further, photobleaching and background
tissue fluorescence affect FLI, and data acquisition time and mo-
tion affect BLI. Although imaging with FLI is in real-time, BLI
requires integration over time of emitted photons to reach an
adequate SNR.
Positron emission tomography (PET) can detect at least a
100 nM concentration with slightly greater concentrations needed
for single-photon emission computed tomography (SPECT). Low
SNR, large voxel size and long imaging time (3–30 min) limit
spatial resolution. In the case of PET, resolution is further com-
promised, because the characteristic dual photon emission that is
captured by the detector ring occurs away from the nucleus of
interest when the emitted positron interacts with an electron,
which occurs at an unknown distance dependent upon positron
energy. Distance travelled by the positron is the least for 18F and is
1 mm, defining a theoretical resolution limit of 1–2 mm voxel
size.
MRI can detect T1 agents in the 10 mM range, and lesser con-
centrations for susceptibility (T2*) agents, such as iron oxide
nanoparticles (IONPs). However, because the effect of T2* agents
is signal loss, detection suffers from SNR limitations as well as poor
specificity when tissues with short T2 are present in the imaged
field. Some investigators have addressed poor IONP specificity by
using ultra-short time to echo (TE) sequences to capture signal and
recognize the T1 shortening effect of IONPs [23]; however, these
pulsing sequences are not widely available. MRI SNR scales linearly
with magnetic field strength, by the square root with imaging
time, and radiofrequency (RF) coil type and size that captures
signal with sufficient SNR at a desired depth. Under ideal opti-
mized in vitro conditions, MRI can resolve a single IONP-labeled
cell [24].
Magnetic particle imaging (MPI) is a newly described imaging
technique that was first reported by Gleich and Weizenecker in
2005 [25]. Whereas MRI interrogates and detects signals from
protons and the influence of contrast media on their behavior,
MPI directly interrogates and detects signal from IONPs, where
core size is ideally monodispersed and in the range of 20–40 nm.
Because signal is only received from IONPs, images are analogous
to nuclear imaging (tracer signal without background signal) or
hotspot imaging, but signal is quantitative. Spatial resolution is
slightly less than 1 mm3. Signal is acquired 1 voxel at a time, and2D or 3D volumes are acquired by raster scanning the voxel
through the volume of interest. Raster scanning is the processing
of sweeping the readout point through the volume of interest from
right to left, anterior to posterior and superior to inferior. MPI
sensitivity is expected to be slightly worse than PET imaging [25–
29] but could be improved with instrument and formulation
optimization. Its main limitation is that MPI requires new MR
instruments, and has to date been limited to imaging mice and
rats. MPI and its required IONP formulations will face significant
challenges when translated to image human subjects.
X-ray computed tomography (CT) is the least sensitive modali-
ty. It requires mM concentrations for detection but boasts the
highest spatial resolution of about 20 mm in vivo in small animals
and 100 mm in human subjects. SNR is dependent on radiation
dose and reporter concentration.
As noted with all these techniques, as spatial resolution
increases (CT > MR > SPECT > FLI) in vivo reporter sensitivity
decreases. Ultrasound (US) stands alone in this regard. It provides
high spatial resolution, exquisite sensitivity to its reporter: micro-
bubbles (MB), and can do so with real-time imaging at the bedside.
US spatial resolution scales with transmission frequency. It can
resolve from tens of mm at 40–80 MHz down to 1–2 mm at 2 MHz.
Unfortunately, the higher frequencies are highly attenuated,
reaching depths of 1 cm at 40–80 MHz and 20 cm at 2 MHz.
MBs of perfluorocarbon (PFC) vapor encapsulated in a phospho-
lipid monolayer are 1–3 mm in diameter, are highly elastic and
oscillate in the mm scale becoming strong US transmitters. The
oscillations produce characteristic frequencies that allow the re-
construction of MB-only images allowing the detection of single
MBs in vitro [30] and a single cell loaded with MBs in vitro and in vivo
[31]. This exquisite sensitivity allows the use of miniscule diag-
nostic doses 5  108 MBs that are administered in 0.1–1.0 ml
total volume depending on the formulation. MB-specific US im-
aging is somewhat analogous to photoacoustic imaging (PAI),
except that sound generation is accomplished with an ultrasound
pulse and the point sources are the MBs in the insonated field.
However, unlike PAI, MB-specific US imaging can reach >15 cm
depth of field.
PAI has been introduced and made feasible in recent years. PAI
transmits light into tissues that reach specific absorbers that heat,
expand and cool rapidly, generating a soundwave detectable by
an external array transducer. Detected sound is then used to
generate an image of the point sources in the field of view. PAI
is a hybrid technique that is more like optical imaging than US.
The advantage of PAI over optical imaging is that light absorption
that occurs deeper in tissues can be resolved because generated
sound is not attenuated at these depths, and the time of arrival of
US signal allows the distinction of the far field from near field
signal. Further, because generated sound travels one-way from
the point sources to the detector, the generated images have
higher spatial resolution than standard US. Similar to optical
imaging, PAI is depth limited; however, the power of the external
light source can be adjusted to radiate sufficient energy into
tissues 1–3 cm deep to generate sound. Similar to optical imaging,
PAI also enables spectral specificity to recognize different absorb-
ers such as oxy- and deoxy-hemoglobin. When MSCs are loaded
with gold nanoparticles, an ideal PAI reporter, SCs can be
detected in vivo [32].www.drugdiscoverytoday.com 495
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variables related to the scanner, patient size and motion and
attenuation make quantification with SPECT challenging. Similar
limitations affect reporter quantification by US and PAI. Although
US does not provide accurate absolute MB concentration, it does
provide accurate relative difference in MB concentration between
adjacent tissues within the same imaged field. Recently introduced
sub-voxel resolution with MB suggests that an accurate MB count
can potentially be provided over the entire field of view [33,34]. In
addition to the same challenges as US, PAI also suffers from light
attenuation that is different for each spectral wavelength.
Discussion of advantages and limitations of each specific imag-
ing approach as they relate to SC imaging are presented below and
in Table 1. Note that, with advances in computer and software
capabilities, image fusion has become prevalent in the clinic. It
enables the combination of PET – the highest sensitivity in vivo
imaging tool – with the highest spatial resolution tool of CT or
MRI. Fusion of real-time US imaging of patients that had been
scanned with PET, CT or MRI, providing a 3D dataset, is currently
used following either automatic co-registration or by use of fidu-
cial markers. Although US fusion has not been used for molecular
imaging, it is currently used in the clinic to biopsy lesions better
seen on PET, CT or MRI under US guidance, which is more cost-
effective and can be done at the bedside. Selected recent publica-
tions describing some aspects of SC labeling, imaging and tracking
in vivo are shown in Table 2.
Advantages and challenges of SC imaging methods
Radionuclide imaging (PET and SPECT)
Nuclear imaging, particularly PET, has the highest in vivo sensitiv-
ity at a practical field of view, enabling a large array of labeling
approaches to be deployed for SC applications in clinical practice.
Further, the quantitative capabilities of PET, combined with its
exceptional sensitivity, have made it the most popular imaging
modality for SC tracking and assessment of cell viability [9,12–
14,17]. Although PET and SPECT use radiotracers, the two tech-
nologies are significantly different [9,12–14,17]. There are several
positron-emitting nuclei used in the clinic for PET imaging that
vary in decay half-life from minutes (15O and 13N) to 1–2 h (18F and
68Ga) to nearly 13 h (64Cu), with 18F being the most commonly
used tracer. The importance of half-life in direct SC labeling is that
it limits the temporal window to label, administer and track cells as
they home and accumulate in their target tissue. By contrast,
SPECT radiotracers such as indium-111 (111In) or metastable tech-
nicium-99m (99mTc) emit gamma rays that are detected by a
rotating gamma camera [35,36]. Compared with PET, SPECT has
a lesser spatial resolution, and the lower gamma energy is more
attenuated in the body; however, the half-life of its radiotracers:
hours to days, is more favorable for SC labeling and tracking
[17,36]. 111In for instance has been used to label SCs for trafficking
and biodistribution studies in large animal models [37,38]. Diverse
tracers have been used for SC imaging with PET and SPECT, such as
18FDG (fludeoxyglucose), 64Cu-PTSM (pyruvaldehyde-bis(N4-
methylthiosemicarbazone)), 111In-oxine and 99mTc-HMPAO (hex-
amethylpropylene amine oxime) [12,14,17,39]. 18FDG is the most
commonly used PET tracer. It mimics glucose but is trapped
intracellularly. Its rate of cellular uptake correlates with the cell’s
metabolic rate; however, for SC imaging it is used as a label before496 www.drugdiscoverytoday.comgrafting [40]. Although it provides high sensitivity and low cyto-
toxicity, its half-life of 110 min makes it less suitable for longitu-
dinal studies to monitor SC biodistribution and homing [12,41].
Because gamma-emitting radiotracers emit different energies,
SPECT provides the option of dual-tracer imaging, for example 99
mTc (149.5 KeV) and 111In (144 and 218 KeV) have been used to
track different SC populations [42,43]. Whereas 111In offers a
longer monitoring window, 99mTc can be given at higher doses
because of its shorter half-life, to improve SNR for higher spatial
resolution [14,36]. Several groups have directly labeled NSCs and
MSCs with either 18FDG [44,45] or 99mTc-HMPAO [46]. There are
several shortcomings to directly labeling SCs with radiotracers
[13,14,17,37,42]. This approach is unable to recognize living from
dead cells, is susceptible to tracer dilution because of cell division
and migration, has a limited imaging window owing to relatively
short decay times, delivers ionizing radiation potentially affecting
SCs and, most importantly, imaging tracks the label not the SC
[13,14,17,37,42]. To overcome the limited imaging time window,
52Mn (5.5-day half-life) as well as 89Zr (3.3-day half-life) were
proposed, in addition to their longer half-lives, to have excellent
stability and labeling efficiencies [36,47,48].
A better and more powerful approach is the use of reporter genes
to detect gene expression to not only image SCs multiple times
over a very long observation window but to also confirm cell
viability [12,14,17]. There have been three different approaches.
The best known and most widely used reporter genes for PET and
SPECT imaging include the herpes simplex virus type 1 thymidine
kinase (HSV1-tk) which is recognized as a hotspot where cells
accumulate. HSV1-tk can be imaged with PET using 18F-labeled
acycloguanosine analog or fluoro-3-(hydroxymethyl)butylgua-
nine ([18F]FHBG). The second approach is to have the SC trap
reporters in a region not known to accumulate the reporter, such
as the sodium iodide symporter (NIS), a trans-membrane protein
responsible for iodine transport in thyroid cells. SC accumulation
is detected if SCs expressing NIS reside in tissues not known to trap
iodine [9,13,16,49]. Similar to NIS, the third approach is when SCs
express a receptor in tissues not known to have such a receptor. For
example the expression of dopamine D2 receptor (D2R) which is
normally predominantly found in the striata nigra. D2R expression
is imaged with PET following the administration of 18F-labeled
fallypride, a dopamine ligand [50]. Gene reporters enable SC
imaging at any time and at multiple time points by administering
the radiotracer to detect the expressed protein [14,16,51]. NIS
imaging can also be done with 124I for PET and 123I for SPECT
[51]. However, if not incorporated in the genome, the concentra-
tion of the expressed protein decreases over time with loss of the
gene to natural decay and dilution because of cell division and
migration.
MRI
MRI-based SC imaging provides high spatial resolution and rea-
sonable imaging time (minutes) to noninvasively track labeled
transplanted SCs [52,53]. MRI has been frequently used to monitor
morphological and SC migration after engraftment [14,17]. MRI
detects hydrogen atoms, the dominant atomic species in living
systems. The signal is generated mostly from water and lipid
hydrogens by detecting their resonant frequency which is unique
to the location of a specific voxel within the field of view. Signal
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TABLE 2
Selected recent publications describing some aspects of stem cell labeling, imaging and tracking in vivo
IImaging
method
Cell type Recipient
species
Tracer or contrast agent(s) Purpose Refs
PET Human mesenchymal stem cells Mouse 89Zr—desferrioxamine-NCS PET-based noninvasive in vivo cell trafficking Bansal et al., 2015 [48]
PET Autologous bone-marrow-derived
stem cells (BMSCs)
Human Fluorine 18-fluorodeoxyglucose (F-FDG) To find administration methods for BMSCs in diabetic
patients
Sood et al., 2015 [40]
PET hBMSCs Mouse Sodium iodide symporter (NIS) reporter gene Hypoxia-based imaging and therapy strategy to target
expression of the NIS gene to experimental hepatocellular
carcinoma (HCC) delivered by MSCs
Muller et al., 2016 [138]
PET-CT Hematopoietic stem cells Mouse Fluorine 18-fluorodeoxyglucose (F-FDG) To investigate hematopoietic stem cell homing efficacy Faivre et al., 2016 [41]
SPECT Neural stem cells (NSC) Mouse (111) In conjugated mesoporous silica
nanoparticles (MSN)
Noninvasive tracking of therapeutic NSCs toward
glioblastoma
Cheng et al., 2016 [139]
MRI BMSC or NSC Mouse Superparamagnetic iron oxide nanoparticles
(SPIO)
For tracking,SPIO labeled stem cells in vivo by MRI Kim et al., 2016 [57]
MRI MSCs Mouse Gadolinium hybrid iron oxide (GdIO) For dual T1- and T2-weighted MRI for cell labeling and
tracking
Zeng et al., 2017 [66]
MRI Rat adipose derived stem cells
(rASCs)
Rat Caspase-3 sensitive nano-aggregation MRI probe
(C-SNAM)
For noninvasive detection of stem cell apoptosis with MR
imaging
Nejadnik et al., 2015 [140]
US Neural stem cells (NSC) Mouse Microbubbles For ultrasound imaging in vivo Cui et al., 2013 [31]
US Neural stem cells (NSC) Mouse Microbubbles For ultrasound SC transfection in vivo Tavri et al.,2013 [18]
US Rat bone-marrow-derived MSCs Mouse Microbubbles For the efficient transfection of MSCs Haber et al., 2017 [141]
US Endogenous mesenchymal stem/
progenitor cells (MSCs)
Mini-pigs Microbubbles For in situ bone tissue engineering via ultrasound-
mediated gene delivery
Bez et al., 2017 [142]
Multimodal: BLI-
MRI
Mouse glial precursor cells Mouse Luciferase gene SPIO-NPs To investigate the allograft survival within the brain Janowski et al., 2014 [105]
Multimodal: FLI-
MRI
hMSCs Mouse Multimodal magnetic nanoclusters (M-MNCs) For gene delivery, directed migration and tracking of SCs Park et al., 2017 [143]
Multimodal: FLI-
CT
hMSCs Mouse Multifunctional stem cell nanotracer (M-NT) For gene delivery and tracking stem cells Park et al., 2017 [144]
Multimodal:US-
MRI
hMSCs Mouse Multimodal silica nanoparticles (SiNPs) Real-time guided cell implantation using ultrasound, and
high-resolution, long-term monitoring of SCs with MRI
Jokerst et al., 2013 [87]
Multimodal: PET/
MRI
hNPC Rat 52Mn; DMT1 Dual-modality PET/MR tracking of transplanted stem cells
in the central nervous system
Lewis et al., 2015 [114]
Multimodal:
SPECT-CT
Rat fetal heart-MSC (fC-MSC) Rat 99mTc HMPAO/PKH26 fluorescent dye To evaluate cardiac perfusion, function and cell tracking
after stem cell therapy in acute myocardial injury setting
Garikipati et al., 2014 [115]
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their average magnetization within the voxel after perturbing
them from equilibrium, which is dependent on their T1 and T2
relaxations. T2* effects result from magnetic inhomogeneity with-
in the voxel. Observed effects of available contrast media are
related to their concentration within the voxel and their influence
on neighboring hydrogen T1 relaxation (T1 agents – increase
signal) or their ability to induce magnetic inhomogeneity (T2*
agents – decrease signal). Although there are pure T2 agents, their
effects are weak. Nearly all successful MRI SC labeling strategies
have been the result of preloading SCs with T1 or T2* agents, with
the latter being most common [38]. Superparamagnetic iron oxide
nanoparticles (SPIONs) 5–150 nm in size, depending on formula-
tion, are the dominant T2* agents used, owing to their high
relaxivity and excellent biocompatibility [19]. SPIONs can be
easily incorporated within SCs in cell cultures that become visible
in vivo as regions of signal loss [54], and have been shown to have
no effect on SC viability, differentiation and therapeutic efficacy
[55]. In early clinical studies, SPION labeling was used to track
MSCs in patients with multiple sclerosis and amyotrophic lateral
sclerosis [56], but have since expanded to track various SC types
[4,57–59]. The size of iron oxide particles used has a marked effect
on T2 shortening, where larger micron particles (MPIOs) have a
several-fold greater effect than their smaller counterparts
(SPIONs). Further, MPIOs improve labeling efficiency and particle
retention. Their greater relaxivity has allowed the detection of
smaller numbers of labeled SCs [60]. MPIO-labeled SCs have been
used in cell-based therapies, regenerative medicine, as well as
several types of human-derived normal and cancer SCs including
glioma and glioblastoma [61]. The major limitations of iron-oxide-
based labeling is their low uptake by SCs and more-important,
particle dilution with cell proliferation and migration, decreasing
detection [62]. Further, as with many reporter-labeled SCs, imag-
ing tracks particles not SCs, leading to detection errors.
Chelated gadolinium-based reporters are the most widely used
T1 agents. They increase MR signal easing target recognition so
long as the target:background contrast:noise ratio is sufficient [14].
To achieve intracellular trapping, novel approaches of conjugating
Gd in nanoparticles such as gold have been developed as efficient
MRI contrast agents for molecular and cellular imaging [63–65]. In
a recent study, biocompatible Gd hybrid iron oxide (GdIO) nano-
composites for dual T1- and T2*-weight imaging of stem cells were
reported [66]. They demonstrated that the GdIO did not affect SC
viability, proliferation or differentiation capacity [66]. However,
these novel SC-labeling agents are too early in their development
to truly assess their potential.
MR can image nuclei other than hydrogen, and 19F has drawn
most interest. 19F is the most abundant form in nature and its
resonance frequency is very close to that of the hydrogen that can
be detected with properly tuned RF coils using most MR systems.
19F resides in cancellous bone in living systems and is not detect-
able in vivo. Unfortunately, despite the absence of background
signal, 19F signal is low requiring much higher concentrations
than hydrogen-based contrast agents for detection [67,68]. The
highest concentration of exogenous 19F is provided by PFCs that
are typically composed of carbon and fluorine atoms that are
immiscible in water and must be administered as emulsions
[69,70]. These molecules are generally inert in living systems498 www.drugdiscoverytoday.comand are eliminated by exhalation with total body residence time
ranging from minutes to years depending generally on their
molecular weight. When cells are loaded with PFC emulsion
particles, they can be tracked in vivo, and can be quantified
[14,17,71,72]. Because these molecules are extremely inert, they
have minor or no effect on cell viability, proliferation or differen-
tiation [73]. Rose et al. labeled the stromal vascular fraction, which
is a collection of cells, some of which are regenerative and are
collected from liposuction material with CS-1000, a 19F agent
intended for a Phase I trial (clinicaltrials.gov identifier
NCT02035085). They were able to detect 2  106 cells at 5 mm
depth at 3-Tesla in a silicone phantom [74]. The major disadvan-
tage of 19F MRI is the relatively low signal and limited loading
capacity of cells requiring 4  104 cells per voxel for detection [75],
which could be improved by using stronger magnets, longer
acquisition times or shortening 19F T1 relaxation time [76]. Like
all labeling with reporters, emulsion particles are also affected by
dilution related to SC proliferation and migration.
There have been attempts at MR detection of gene expression,
the ultimate labeling strategy for SC imaging in vivo. Unfortunate-
ly, the successes achieved with PET scanning have not been
realized by MRI, mostly because of limited signal [12–14,17,77].
For instance, metalloproteins and metal ion transporters such as
ferritin can be made to overexpress in transfected cells to enrich
their intracellular content of iron and increase their detection on
MRI [19,47,78]. A novel approach, described by Mukherjee et al.,
uses aquaporin 1 (AQP1) which increases transmembrane water
transport in transfected cells, and therefore water diffusion rates,
increasing contrast on diffusion-weighted MRI [79]. The use of
agents that enable chemical exchange saturation transfer (CEST)
have become valuable tools for the detection of biomarkers such as
temperature and pH [80,81], and have also been used to monitor
the distribution of an extracellular hydrogel matrix after in vivo
implantation [82].
MPI
MPI is a MR technique that requires different instrumentation to
MRI. It uniquely detects superparamagnetic nanoparticles. Fortu-
nately there is ample literature on labeling and tracking SCs with
IONPs. MPI provides a more robust imaging technique to detect,
localize and recognize IONPs with greater specificity than MRI.
Because there is no background signal, high contrast images are
produced, but require a 3D dataset such as that acquired with
standard MRI or X-ray CT to anatomically localize detected sig-
nals. As with other direct labeling techniques, MPI images the
reporter not the cell, and suffers from signal loss as cells divide and
migrate.
Similar to protons, the magnetic moment of each IONP is
randomly oriented with no resultant magnetic moment within
a voxel. When a magnetic field gradient is applied, all particles
become totally aligned with the magnetic field within a short
distance from the zero-field – the point of inflection of the sigmoid
shaped magnetization curve. The steeper the transition between
the negative and positive magnetization curve the smaller the
voxel size, which is also controlled by particle size and gradient
strength. MPI takes advantage of this nonlinear behavior that is
unique to superparamagnetic particles to limit detection to a small
volume (1 mm3) that contains 10 mM of IONPs with a 20 nm
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Because signal is acquired one voxel at a time, which is raster
scanned throughout the imaging volume, imaging time is depen-
dent on the number of voxels acquired within the volume which
ranges from milliseconds to several minutes depending on the
voxel density desired. Faster imaging to achieve real-time scanning
has been proposed [83]; however, these speeds continue to be at
the expense of resolution and SNR.
MPI is extremely useful in SC tracking and assessing biodistri-
bution over time in mice [27,84], and is quantitative with signal
linearly tracking iron concentration regardless of aggregate geom-
etry [29]. For instance, MPI showed that IONP-labeled MSCs
injected systemically became trapped in the lungs, and subse-
quently migrated to the liver [84]. Using efficient cell labeling
with IONPs and a prototype MPI system, 3–5  104 cells could be
detected per voxel, which is similar to 19F MRI with PFC labeling.
The minimum number of cells that could theoretically be detected
could be improved to <1000 cells per voxel with improved IONP
formulation, instrumentation and cell labeling. MPI is dependent
on IONP core size which defines signal and voxel size, with
Resovist1 producing a four-times greater signal than the older
formulation Feridex1. Unfortunately, both of these clinical agents
are no longer available creating yet another hurdle for translating
MPI to the clinic. Several new formulations have been proposed
specifically designed for MPI, which will require regulatory clear-
ance before translation.
Ultrasound
Whereas several US contrast agents have been proposed over the
years, PFC liquid droplets proposed in the early 1980s reached the
clinic but required a minimum of 0.5 g (w/v)/kg dose to be visible on
B-mode imaging [85]. Although SCs loaded with PFC are detectable
by 19F MRI, the amount of liquid PFC loaded and the number of cells
used for MR detection are insufficient for standard US detection.
However, should SCs be loaded with PFC vapor as 1–2 mm MB, a
single cell can be detected in vivo (Fig. 2) [31]. This exquisite sensi-
tivity to MB is due to the PFC vapor that stabilizes them and the
unique frequencies emitted when MB oscillate in the US field.
Further, when MBs are intracellular they not only survive for days
rather than minutes when they are free in plasma, but they also
become less sensitive to destruction when exposed to US [31]. US-
based SC imaging is not only the most sensitive of the available in
vivo imaging techniques but US can also track MB-labeled SCs for
days [31,86,87]. US tracking of SCs has been reported using SC
labeling with MB, acoustically active liposomes and theranostic
mesoporous silica nanoparticles [88,89]. As an alternative to directly
labeling SCs, Kuliszewski et al. used gene expression to detect SCs
[90]. Engrafted endothelial progenitor cells (EPCs) were made to
express a unique surface receptor that was used as a target for MB
carrying the specific ligand to detect the implanted SCs [90]. With
this approach, SCs must be exposed to blood to be able to interact
with MB, because the 1–3 mm MB size limits them to the intravas-
cular space. Should US agents be made nanoscale and targeted, gene
expression that expresses surface receptors can be used to detect SCs
in vivo and confirm viability. Once SCs are loaded with MB, they
experience the same radiation force experienced by free MB forcing
them against the deeper vascular wall to enhance targeting, adhe-
sion and potentially migration [91,92]. In fact, MB labeling for SCdetection need notbe intracellular, rather, MB can be targeted to and
attached to surface receptors [91,92].
The lipid shell of MB used for SC labeling can also be loaded with
DNA, which upon exposure to US can effectively deliver genes to
transfect the labeled SCs (Fig. 2) [18]. Should the pressure required
for transfection be greater than that required for detection, it
would be possible to monitor SC accumulation at the site of
interest, and then transfect SCs at the desired time and space to
induce the desired function, as was shown feasible in vitro [31] and
in vivo [18]. Recent developments in high-intensity-focused US
have enhanced the efficacy of SC therapy [93]. Despite these
advances and the high sensitivity of US, US reporters loaded within
SCs before engraftment suffer the same drawback of dilution with
cell division and migration. However, we suspect that, upon cell
death, MB will become free and short lived eliminating the label
from the imaging field, suggesting that visible signal is indicative
of viable cells.
Inspired by gas-vesicle-forming photosynthetic microbes,
which produce these vesicles to control the organisms’ buoyancy,
Shapiro et al. characterized these gas vesicles that also contain iron
and showed that they are active as US and MRI contrast agents [94–
96]. The genetic precursors of these complex protein vesicles were
then determined and used as a US and MRI gene reporter system
[96]. The extremely high sensitivity of US should prove to be a
powerful tool to label and track SCs.
PAI
Several PAI contrast agents have been proposed focusing on
unique absorbers. A novel PFC emulsion-based PAI agent incor-
porates gold nanoparticles within the PFC phase. Not only do
these emulsions absorb transmitted light but the localized heating
evaporates the surrounding PFC liquid to generate nanobubbles
increasing US signal [32]. Prussian blue nanoparticles have also
been proposed as PAI agents with strong optical absorption in the
near-infrared region [97]. Their optical properties allow the use of
730 nm lasers, improving light penetration, with adequate sensi-
tivity as determined by subcutaneous injections (theoretical limit
of 200 cells/mm3). Further, the administration of 5  104 MSCs
could be followed in mice for 14 days [97]. Similar results were
reported using hESC-CMs in living mouse hearts labeled with
semiconducting polymers that also absorb in the 700 nm range
[98]. With this label, they also showed the detection limit to be
200 cells/mm3 following subcutaneous injection.
Optical imaging
Fluorescence and bioluminescence are the two major optical imag-
ing methods that are widely used for preclinical experiments to
assess location and functional status of SCs [17,79]. FLI transmits
light into tissues to excite fluorophores and receives the emitted
fluorescence. It provides excellent sensitivity and is able to image
and track SCs at the cellular level [14,42]. Classically, cells are labeled
with fluorescent dyes or engineered to express a fluorescent protein
preferably inthe near-infrared rangetoenable greater imagingdepth
for in vivo detection [99]; however, FLI is practical in only mice or
superficial structures owing to severe light scattering and absorp-
tion, as well as limited emission per molecule and photobleaching,
limiting translation [12,14,36,99]. To maximize reporter labeling,
fluorescent polymeric NPs and quantum dots (QDs) have been usedwww.drugdiscoverytoday.com 499
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FIGURE 2
This figure was adapted, with permission, from [31]. (a) Single trypsinized neuroprogenitor cell (NPC) containing multiple microbubbles (MB) (arrows) appearing
as black circles with a white center owing to light diffraction (scale bar = 10 mm). (b) NPC culture acquired 48 h following ultrasound exposure of GFP-carrying
MB loaded within NPC. (c–h) Confocal microscopy of DiI-labeled MB showing the time course of internalization of several MB by NPCs (arrow) that disappear as
they move out of the 0.8 mm slice (scale bar = 10 mm). (i) MB-only and its corresponding B-mode images of a mouse liver acquired with a 2.4 cm depth of field,
5 days after the i.v. administration of 1.5  106 MB-labeled NPCs shortly following 20 mg sodium nitroprusside given i.v. to minimize NPC lung trapping. Note
that at 5 days several MB-labeled NPCs are still visible (red arrows). Scale bars in a and c–h = 10 mm.
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to label and monitor SCs [15], as well as monitor their accumulation
in wound healing using a chemoattractants [100]. An interesting
method of cell labeling is the direct introduction of reporter into the
cytoplasm using sonoporation with US and MB, or photoporation
with light and gold nanoparticles [101]. Using photoporation,
Xiong et al. showed a several-fold increase in labeling efficiency,
symmetric signal distributed to daughter cells and the reporter
remained visible for 2 months rather than 2 weeks [101].
Although novel FLI techniques have been proposed to improve
signal recognition from tissue autofluorescence using fluorescence
lifetime imaging, imaging deeper than a few millimeters in vivo with
acceptable resolution remains a significant challenge. Fortunately,
however, the majority of studies showed that FLI reporters did not500 www.drugdiscoverytoday.comaffect SC viability or function, but the highest concentration of QDs
caused cytotoxicity [15].
Bioluminescence imaging (BLI) detects light generated in tis-
sues. The typical source of light is when luciferase catalyzes its
substrate luciferin. Cells are typically engineered to express lucif-
erase, and luciferin is typically given intraperitoneally for imaging
[12,14,17,36]. Because catalysis can only occur in living cells, BLI
can track SCs expressing luciferase as well as assess SC viability.
Luciferase can be of firefly or Renilla origin, which catalyze lucifer-
in or coelenterazine, respectively. Because emitted photons have
different wavelengths, both systems can be used simultaneously to
track different SC populations [102]. BLI has been extensively used
for tracking SCs in vivo, including ESCs and NSCs in small animals
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cells can be imaged over a long period after engraftment by merely
administering the substrate [102,103]. Note that photon genera-
tion is ATP-dependent [103], requires oxygen [106] and the sub-
strate must reach the SCs of interest in concentrations sufficient to
generate enough photons for detection within a reasonable acqui-
sition time. Substrate delivery is affected by administration route,
blood flow, serum protein binding capacity, the inhibitory effect
of volatile anesthetics and the general physiological state of the
animal [107,108]. Because emitted photons are also scattered and
attenuated by tissues, the number of photons reaching the detec-
tor limits detection to a shallow depth or requires a longer inte-
gration time. A recent exciting opportunity is the introduction of a
totally synthetic enzyme that catalyzes a synthetic luciferin-like
substrate that has superior biodistribution to luciferin. More im-
portant is that gene expression is fourfold more efficient, catalysis
is sevenfold more effective and the emitted photon is red-shifted at
650 nm (several orders brighter) and can reach the detector from
deeper regions allowing the detection of a few labeled cells and the
ability to detect labeled cells in vivo in real-time [109].
Multimodal imaging
With the advent of rapid computing and the ability to fuse images
acquired by different imaging modalities either concurrently or in
different imaging sessions, it has become possible to combine the
advantages of different imaging techniques [87,110]. The most
developed and clinically used is PET-CT which combines the high
spatial resolution of CT with the high reporter sensitivity of PET [13].
PET-MR is becoming more available, taking advantage of the added
capabilities afforded by MRI. In addition to spatially combining
imaging data, information gleaned from one technique can be used
to improve image quality of the other, such as adjusting for tissue
attenuation in PET imaging based on X-ray attenuation defined by
CT [111]. These added capabilities have brought a new perspective to
SC imaging. Multimodal imaging has allowed the use of different
tracers for multiparametric imaging [73,112]. Thus, a combination
of PET or SPECT with MRI can provide superior resolution, higher
tracer sensitivities, as well as greater functionality [113]. Combina-
tions of MRI with PET [114], BLI with MRI and SPECT with FLI have
been reported [115]. For instance, the combination of MRI and BLI
was successfully used to assess SC fate in vivo, enabling functional
evaluation in myocardial infarction [116].
Key challenges in clinical translation
Noninvasive SC imaging and monitoring can provide a compre-
hensive assessment of SC therapy. Even though successes have
been achieved in preclinical models, translation to the clinic has
met with several challenges. In addition to the fact that SC imag-
ing strategies and efficiencies have numerous advantages when
developed in rodents, differences in physiology, pharmacokinet-
ics, basal metabolic rates, among others, are considerable, limiting
prediction of clinical success [117]. Transitioning to larger animal
models and those with more-appropriate physiology to humans
could bridge the translational gap.
SC survival, biodistribution and differentiation
Success of SC therapy in the clinic has been unpredictable,
probably owing to inconsistent SC survival, varied biodistribu-tion with entrapment in the liver, spleen, lung and bone marrow
in case of systemic administration, and success of engraftment if
directly delivered to the site of interest, and ultimately SC differ-
entiation into the desired function sought. For instance, it was
shown that <10% of administered SCs were engrafted in the
tissue of interest – the remainder became trapped in the reticulo-
endothelial organs or died shortly after implantation [118,119].
Imaging provides the opportunity to ensure that SCs are
engrafted in the tissue of interest, are alive and ultimately differ-
entiated into the desired function. Unfortunately, as the number
of SCs and reporter concentration decreases, it becomes more
challenging for imaging to detect and assess the engrafted SCs
[14]. Tracking SCs to confirm they reached the tissue of interest is
the easiest problem to navigate because loading SCs with repor-
ters can be optimized to achieve the desired sensitivity and spatial
resolution for the imaging modality used. Further, in the case of
radioisotopes, the appropriate decay half-life has to be long
enough to provide a sufficient imaging time window to track
the SCs. Although indirect labeling with reporter genes infers SC
viability and is the preferred technique, their detection in vivo is
more challenging than direct labeling, mostly because of limited
reporter concentration which is dependent on robust gene ex-
pression and the presence of a sufficient number of SCs at the site
of interest. Further, stably transfected engineered cells raise safety
concerns.
Safety concerns
Clinical implementation of SC-based therapy has been hindered
by the potential for tumorigenesis. SCs have natural tropism to
cancer and can be induced by the tumor to promote growth.
Unfortunately, SCs also have the potential to form tumors them-
selves, particularly when ESCs or iPSCs are used. Successful moni-
toring of delivered SCs could allow the detection of early tumor
formation. Although short-term monitoring of SCs in vivo has been
achieved in clinical trials using radionuclide-based methods, long-
term monitoring is still problematic and no clinically acceptable
technique has emerged.
Complex regulatory requirement
The inclusion of SC imaging in clinical trials adds complexity to
the regulatory process requiring details of the labeling methods,
labeling efficiency and label concentration, as well as the effect of
labeling on SC viability, proliferation, migration, function and
tumorigenicity. It is therefore imperative that labeling does not
impact SC potency, interfere with their function or introduce a
new undesired effect. These safety requirements increase further
when SCs are engineered to express a reporter gene. In addition to
validating gene expression, stability and long-term passaging and
lack of tumorigenesis need to be confirmed [12,13]. If multiple
genes are incorporated, for example the addition of a suicide gene,
expression of the genes and the programed functions need to be
confirmed, for example cell death when the suicide gene is trig-
gered [13]. In addition, SC dose, administration schedule, route of
administration, intended sites and target organ accumulation
need to be defined [120]. Using nonclinically approved products
during the manufacturing process should be avoided to ease
translation, such as the use of fetal bovine serum or dimethylsulf-
oxide.www.drugdiscoverytoday.com 501
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Given the limitations of spatial resolution, reporter sensitivity,
depth of field or labeling strategies of existing imaging methods,
advances in image fusion enabling multimodal imaging holds great
promise in supporting SC imaging in clinical trials. In addition to
combining imaging advantages of each of the two fused modalities,
different reporter systems detectable by each of these imaging
techniques enables strategies that can improve tracking, recognize
engraftment and confirm functional differentiation. Novel labeling
strategies that can increase short-term monitoring time to enable SC
tracking for 1–2 days to ensure that they reach their intended
destination, and strategies that enable long-term monitoring to
assess migration, proliferation, function and survival, while not
affecting SC function or inducing malignant degeneration, are
needed. In addition, including the possibility of interacting with
engrafted SCs using US or light to inducea desired functional change
with spatial and temporal specificity would be of great benefit for
specific applications, particularly if the desired change initiates a
therapeutic effect or activates a SC suicidal pathway.
SCs have generally been administered intravenously to mimic
endogenous physiological SC delivery. However, because a large
fraction becomes trapped in the lungs because of surface adhesion
molecules [121,122] or as aggregates, intra-arterial delivery might
be more effective at increasing SC concentration in target organs
[122]. Ineffective or temporarily effective SC therapy could in part
be due to suboptimal SC delivery [123]. Strategies to more effec-
tively deliver SCs to tissues and organs have been proposed aiming
to enhance therapeutic efficacy at a reduced SC dose [124–126].
Such approaches, for example image-guided SC delivery, have502 www.drugdiscoverytoday.combeen used in the heart [127], brain [128], spinal cord [129], liver
[130] and kidney [131]. However, local injections or implantation
could disrupt native tissue architecture and create several adverse
effects [132]. It should be noted that, assuming successful delivery
and engraftment, SCs are potentially susceptible to the pathologi-
cal environment of the host tissue, accelerating SC death or
decreasing potency [133]. Advances in SC genetic modifications,
such as site-specific integration using phage integrases [134],
transcription activator-like effector nuclease (TALEN) [135] or
clustered regularly interspaced short palindromic repeats (CRISPR)
[136], hold great promise. 3D printed tissues have shown remark-
able regenerative capabilities and the progress of 3D printed tissues
has been reviewed by Choi et al. [137]. In their review, the authors
express the need to monitor the viability of the fabricated scaffolds
and the performance of printed tissues in vitro and in vivo to help
advance the field. Our review focuses on SC imaging to support SC
therapy; however, imaging should also be incorporated in trials to
monitor ultimate therapeutic efficacy and safety to better asses the
risk:benefit ratio.
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